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ABSTRACT
Introduction: The selection of a sperm with good
genomic integrity is an important consideration for
improving intracytoplasmic sperm injection (ICSI)
outcome. Current convention selects sperm by vigour
and morphology, but preliminary evidence suggests
selection based on hyaluronic acid binding may be
beneficial. The aim of the Hyaluronic Acid Binding
Sperm Selection (HABSelect) trial is to determine the
efficacy of hyaluronic acid (HA)-selection of sperm
versus conventionally selected sperm prior to ICSI
on live birth rate (LBR). The mechanistic aim is to
assess whether and how the chromatin state of
HA-selected sperm corresponds with clinical
outcomes—clinical pregnancy rate (CPR), LBR and
pregnancy loss (PL).
Methods and analysis: Couples attending UK
Centres will be approached, eligibility screening
performed and informed consent sought.
Randomisation will occur within 24 hours prior to ICSI
treatment. Participants will be randomly allocated 1:1
to the intervention arm (physiological intracytoplasmic
sperm injection, PICSI) versus the control arm using
conventional methods (ICSI). The primary clinical
outcome is LBR ≥37 weeks’ gestation with the
mechanistic study determining LBR’s relationship with
sperm DNA integrity. Secondary outcomes will
determine this for CPR and PL. Only embryologists
performing the procedure will be aware of the
treatment allocation. Steps will be taken to militate
against biases arising from embryologists being non-
blinded. Randomisation will use a minimisation
algorithm to balance for key prognostic variables. The
trial is powered to detect a 5% difference (24–29%:
p=0.05) in LBR ≥37 weeks’ gestation. Selected
residual sperm samples will be tested by one or more
assays of DNA integrity.
Ethics and dissemination: HABSelect is a UK NIHR-
EME funded study (reg no 11/14/34; IRAS REF. 13/YH/
0162). The trial was designed in partnership with patient
and public involvement to help maximise patient
benefits. Trial findings will be reported as per CONSORT
guidelines and will be made available in lay language via
the trial web site (http://www.habselect.org.uk/).
Trial registration number: ISRCTN99214271;
Pre-results.
Strengths and limitations of this study
▪ Hyaluronic Acid Binding Sperm Selection
(HABSelect) is one of the only trials with suffi-
cient power to test the efficacy of a sperm-
selection procedure that has shown some
promise for improving live birth rate but without
conclusive evidence hitherto.
▪ The trial has closely linked clinical and basic
science aspects that makes best use of the
resources provided by participating couples.
Both components will advance clinical and
mechanistic understanding.
▪ Since the intervening embryologist is aware of
the arm allocation, there may be a potential for
subconscious embryo selection bias, particularly
in smaller clinics with fewer staff. This effect,
however, should be mitigated by data capture,
including details of the embryologist involved
and close data monitoring by the independent
steering committee.
▪ There are likely to be potentially confounding
variations in semen quality that could affect the
interpretation of clinical outcomes, but these
should be mitigated by careful recording of
semen profiles and their stratification according
to HBA scoring. A hierarchy of sperm chromatin
quality assays will allow us to minimise the
effects of sample availability while maximising
information content.
▪ Mechanistic work is entirely dependent on the effi-
cient recovery of residual processed sperm from
participating centres following treatment. The
success or otherwise of this recovery process is
very likely to vary among participating centres.
Witt KD, et al. BMJ Open 2016;6:e012609. doi:10.1136/bmjopen-2016-012609 1
Open Access Protocol
BACKGROUND
One in seven couples experience difﬁculty conceiving a
child and rises in the prevalence of infertility and the
number of couples seeking help via assisted reproduc-
tion technologies (ARTs) is now evident.1 2 In 2012,
almost 47 000 couples in the UK alone were treated with
ART, comprising 62 000 treatment cycles, over half of
which involved intracytoplasmic sperm injection (ICSI),
a technique originally developed to treat male infertil-
ity.2 Currently, live birth rates (LBRs) following ICSI
treatment are at an average of ∼24% per treatment
cycle, a rate that has remained virtually unchanged in
the last 10 years. Up to 50% of infertility cases are
thought to have a male factor origin3 and with ICSI fast
becoming the favoured choice for fertilisation irrespect-
ive of the male factor,2 there is a more urgent need for
improvements in its efﬁcacy. To date, however, compared
with egg and embryo quality, relatively little effort has
been expended on improving sperm quality beyond pro-
cessing semen according to WHO guidelines.4 Such pro-
cessing may be less effective for ICSI where the egg itself
offers no effective barrier to direct insemination by
defective sperm, and sperm selection is subjectively
dependent on the treating embryologist.
Sperm chromatin structure plays a vital role in protect-
ing paternal DNA integrity by condensing the sperm
DNA over 10-fold compared with somatic cell nuclei.
Ordinarily, natural selection is effective at screening out
defective sperm that have failed to maintain DNA integ-
rity as they transport through the female reproductive
tract. Importantly, as this ‘triaging’ step is omitted in the
direct sperm transfer of ICSI, a greater understanding of
the relationship between sperm DNA integrity (and con-
versely DNA fragmentation) and embryonic developmen-
tal potential is needed. Numerous studies have shown
clear inverse relationships between sperm DNA fragmen-
tation anomalies in the ejaculate and clinical pregnancy
(CPR) or live birth (LBR) rates in in vitro fertilisation
(IVF).5–10 However, the relationship with ICSI outcomes
is less clear. We, among others, have reported that miscar-
riage is a risk factor in ICSI in relation to sperm DNA
fragmentation,11 12 and this may result from an oocyte-
mediated DNA repair process13–16 that adequately sup-
ports clinical pregnancy (hence the lack of an association
between DNA fragmentation and clinical pregnancy in
ICSI compared with IVF), but may be inadequate to
sustain it with resulting pregnancy loss (PL). There
remains a need to develop more sophisticated techniques
to identify functional spermatozoa from those that are
immotile, have poor morphology, have poor DNA integ-
rity or are simply incapable of fertilising oocytes. ART
sperm preparation including differential density gradient
centrifugation has been found to result in enrichment of
sperm with intact chromatin, which in turn is likely to
improve the chances of a successful clinical outcome.17 18
While success rates are known to vary widely across
clinics, further innovations are needed to improve the
plateaued average LBR of 24% for IVF and IVF-ICSI.
Selecting sperm binding to hyaluronic acid (HA) for
ICSI is thought to be one such innovation. HA is the
natural, non-sulfated glycosaminoglycan secretion of the
cervical mucus and the cumulus-öopherus complex.19
Sperm reaching HA-coated surfaces can bind to and
potentially digest the HA, and their subsequent hyperac-
tivation may further facilitate their reaching the egg.20 21
Immature sperm with excessive cytoplasm appear to
have a lower afﬁnity for HA and higher rates of aneu-
ploidy and DNA fragmentation.22–24 Studies using a
HA-selection procedure for ICSI reported higher
numbers of grade 1 embryos following ICSI,25 an
increase in clinical pregnancy rate (CPR) with a corre-
sponding drop in miscarriage rate26 and most recently, a
signiﬁcant reduction in PL and a signiﬁcantly improved
LBR in this group.27 These outcomes, while encour-
aging, were drawn from relatively small sample sizes that
were insufﬁciently powered to conclusively test the efﬁ-
cacy of sperm selection by HA-binding for ICSI.28 29
HYPOTHESIS
The Hyaluronic Acid Binding Sperm Selection
(HABSelect) trial is designed to test the hypothesis that
selection of sperm for injection using HA binding prior
to ICSI has beneﬁcial effects on clinical outcomes com-
pared with standard ICSI. The trial’s main strength is its
accommodation of clinical and basic science aspects that
are fully complementary. Its parallel, mechanistic investi-
gations will allow us to determine whether HA-binding
mitigates for potentially genotoxic levels of DNA frag-
mentation in patients’ sperm.
METHODS AND ANALYSIS
Study design and objectives
HABSelect is of a phase III, two arm, multicentre,
blinded, efﬁcacy clinical trial with mechanistic evalu-
ation. The primary objective of the clinical trial is to
determine the efﬁcacy of HA-selected intracytoplasmic
sperm injection (physiological intracytoplasmic sperm
injection, PICSI) versus conventional ICSI where the
primary outcome measure will be LBR ≥37 weeks’ gesta-
tion. The primary mechanistic objective is to evaluate
whether HA-selection can compensate for poor sperm
quality and investigate HA-binding score (HBS) in rela-
tion to chromatin integrity and LBR.
Secondary objectives will include a determination of
the impact of the intervention on CPR based on detec-
tion of fetal heartbeat and/or fetal sac at 6–9 weeks’ ges-
tation and miscarriage rate deﬁned as PL after
conﬁrmation of clinical pregnancy. The study design is
detailed in the consort diagram (ﬁgure 1).
Eligibility and recruitment
HABSelect participant couples will recruit from multiple
assisted conception units across England and Scotland.
All participating sites will be recognised teaching institu-
tions (or equivalent) accredited in the performance of
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ICSI fertility treatments and have been initially selected
on the basis of potentially high recruiting capabilities
using records held by the Human Fertilisation &
Embryology Authority (HFEA). Sites commonly have a
mix of NHS and private facilities treating publicly funded
and fee-paying patients. Ethical approvals will include
recruitment not limited to couples receiving NHS reim-
bursed treatment. To facilitate and assist in achieving
recruitment targets, four clinical advisors will be appointed
who will oversee their own centres and those in their
adjacent regional areas. They will be supported by the
National Institute for Health Research (NIHR) Clinical
Research Network, which collects recruitment data on a
monthly basis. All issues arising during the conduct of the
trial will be discussed in regular monthly management
meetings and any unresolved issues referred to one of two
independent trial overseeing committees. Couples will be
identiﬁed as candidates for the HABSelect study by local
clinical or research staff if they have opted for or been
advised to make use of ICSI-based procedures. Normally,
Figure 1 HABSelect consort chart. The chart was designed according to CONSORT guidelines (http://www.consort-statement.
org) and shows the main aspects of the clinical trial and its relationship with clinical and mechanistic outcomes and reporting.
HA, hyaluronic acid; HABSelect, Hyaluronic Acid Binding Sperm Selection; ICSI, intracytoplasmic sperm injection; PICSI,
physiological intracytoplasmic sperm injection.
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routine WHO-based assessment of ejaculate quality is sufﬁ-
cient for men to be selected for ICSI procedures over IVF.
The clinical team will check that the couple meets the
inclusion and exclusion criteria (box 1), and only
couples meeting these criteria will be approached to
provide consent to participate. Screening, conﬁrmation
of eligibility and formal enrolment onto the study will
be followed by the completion of baseline assessments,
and the couple will enter the ICSI clinical care pathway.
The female participant will then start a follicle stimula-
tion regimen according to the treatment centres’ locally
approved protocol.
Randomisation
A 1:1 randomisation of ‘experimental’ of HA-ICSI using
the physiological intracytoplasmic sperm injection
(PICSI) sperm-selection dish (PICSI) versus ‘control’
standard vigour with morphology ICSI sperm selection
(ICSI) where the inclusion of polyvinylpyrollidone slows
the sperm down sufﬁciently for pipette capture.
Randomisation will take place within 24 hours prior to
the insemination and will be performed by an autho-
rised member of staff at the centre (typically the embry-
ologist), using a custom, web-based 24-hour automated
randomisation system employing a computer-generated
minimisation algorithm according to maternal age
(<35, ≥35), paternal age (<35, ≥35), number of previous
miscarriages (0, 1–2, >2) and hormonal indicators of
ovarian reserve used currently in the participating clinics
(follicle stimulating hormone (FSH) <6.0, ≥6.0 miU/mL
or anti-müllerian hormone (AMH) <17.0, ≥17.0 pmol/L
when FSH is not available). Minimisation will not include
HBS. Minimisation factors will be balanced separately
within each site. Research nurses and treating clinicians
including principal investigators will be blinded to arm
allocation.
Withdrawal criteria
Participants can withdraw at any time prior to egg collec-
tion or where, in the opinion of the investigator or the
care providing clinician or clinical team, it is medically
necessary to do so. Study personnel will make every
effort to obtain and record information about the
reasons for discontinuation, any adverse events and to
follow-up the women for all safety and efﬁcacy outcomes,
as appropriate. A clear distinction will be made as to
whether the patient is withdrawing from trial treat-
ments/procedures while allowing further follow-up, or
whether the patient refuses any follow-up. If a patient
explicitly withdraws consent to have any data recorded,
their decision will be respected and recorded on the
electronic data capture system. All communication sur-
rounding the withdrawal will be noted in the patient’s
records, and no further case report forms (CRFs) will be
completed for that patient.
Trial intervention and participant follow-up
The HA-ICSI intervention will use the Conformité
Européenne (CE) marked and Medicines and
Healthcare Products Regulatory Agency (MHRA)
approved PICSI dish (Sterling Scientiﬁc, USA) alongside
their Hydak HBS slide. These products offered the best
prospect for assuring continuity of supply, quality
control and relative ease of use. (ﬁgure 2). An alterna-
tive medically approved product (Sperm-slow) was con-
sidered by the clinical advisory teams on the evidence
that it and PICSI have similar efﬁcacy30 but was rejected
in favour of PICSI, which has been more widely reported
in the context of CPR and miscarriage.26 27 HBS will be
obtained from both arms of the trial, but only the
HA-ICSI arm will make use of the PICSI plates. There
are no other planned interventions in the study. All
protocol-required assessments and data collection will
be recorded on trial-speciﬁc CRFs at each site. Any
remaining sperm sample will be processed and frozen
stored (four equal aliquots per sample) according to
the requirements of the mechanistic research evalu-
ation. The trial will also make use of the approved
tissue bank to facilitate transfer of the samples between
participating sites and the mechanistic research
laboratories.
Following ICSI, couples will resume standard care with
no further scheduled trial-speciﬁc follow-up. However,
the couples participating in the HABSelect trial will have
their unique ID number allocated on enrolment to the
study and linked to the female partner’s patient record
so that routine fetal/pregnancy outcome data can be
captured and recorded on the web-based database fol-
lowing the template required by the HFEA. No patient
identiﬁable information will be entered. All data sharing
Box 1 Study eligibility criteria
Inclusion criteria
1. Couples able to provide informed consent.
2. Couples undergoing ICSI procedure.
3. Female:
A. Age: 18–43.
B. Body mass index: 19.0–35.0 kg/m2.
C. FSH level 3.0–20.0 miU/mL and/or AMH ≥1.5 pmol/L.
4. Male:
A. Age: 18–55.
B. Able to produce freshly ejaculated sperm for the treatment
cycle.
Exclusion criteria
1. Couples who have not consented prior to ICSI will be
ineligible.
2. Couples using non-ejaculated sperm.
3. Couples using donor gametes.
4. Men with vasectomy reversal; cancer treatment involving any
chemotherapy and/or radiotherapy in the past 2 years.
5. Previous participation in the HABSelect trial.
6. Split IVF/ICSI procedures.
7. If FSH and AMH are tested and either measure falls outside the
accepted range.
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between clinical and mechanistic arms of the study will
follow principles of good Information Governance (www
http://systems.hscic.gov.uk/infogov).
Mechanistic study
A key aspect of HABSelect is the recovery of residual pel-
leted sperm for assessment of male patients’ sperm
genomic integrity based on measures of DNA
fragmentation and chromatin compaction or condensa-
tion state (TUNEL, Comet, HALO, Acridine Orange,
Aniline Blue and chromomycin A3 staining; see ﬁgure
3A). Use of several independent measures of paternal
genomic integrity will address the issue of assay variabil-
ity.7 8 31–36 This strategy will help maximise the informa-
tion we obtain from these samples and assist
interpretation of data arising from past and future
studies that make use of any of these assays.
Samples will be selected initially on whether a clinical
pregnancy was reported or not (blinded to arm alloca-
tion but balanced numbers), and the process reiterated
until ∼1200 samples have been tested with two or more
of the same assays across three (<50% 50–65%, >65%)
sperm HBS strata. The precise number of assays will
depend on sample quality, as measured by cytology,
based mainly on the number of recovered sperm. A hier-
archy of assays (ﬁgure 3A) also takes account of limited
sperm numbers following cytological inspection that
may be encountered in any sample, while making provi-
sion for maximising information content. In addition to
cytology, should only two tests be possible, the hierarchy
will always include one assay of DNA fragmentation
(Comet or TUNEL) and one assay of chromatin com-
paction (Aniline Blue or CMA3). HALO overlaps both
variables and will be used where only one assay is pos-
sible. The mechanistic sample size is based on the struc-
tural equation modelling (SEM) linking the clinical and
mechanistic outcomes (‘Statistical considerations’
section).
Statistical considerations
Clinical sample size and estimates
We estimate from HFEA audit data2 that ∼6000 couples
per annum undergoing ICSI will be eligible across all
centres. Assuming a LBR following ICSI of ∼24%,34 a
minimum of 3266 couples will be needed to detect a 5%
improvement in LBR (25–29%) at ≥37 weeks with 90%
power. A 10% loss to follow-up is accommodated
although it is anticipated that compliance will be high
given the lateness of randomisation and the routine
nature of collecting data on biochemical pregnancy
(BP), clinical pregnancy (CP) and live birth (LB) data
in this population.
Clinical statistical analysis
Our unit of analysis will be the couple. Baseline
characteristics will be tabulated. We have elected to
focus on the outcome of the ﬁrst fresh ICSI cycle in
each randomised couple and powered the trial accord-
ingly. The analysis will be by intention to treat. Numbers
of couples at different stages of the trial are summarised
in the CONSORT diagram (ﬁgure 1).
The primary outcome is the proportion of women
who experience a live birth ≥37 weeks. Secondary out-
comes are the respective proportions of women who
experience the following: a clinical pregnancy (presence
of a fetal heartbeat or fetal sac at 6–9 weeks’ gestation);
Figure 2 (A) Hydak slide showing twin chambers used to
obtain sample % HBS. (B) PICSI plate showing channels
(arrows) into which sperm suspensions are introduced.
Mature, motile sperm migrate towards the hyaluronic coated
dots at one end of each channel where they bind.
(C) Photomicrograph from time-lapse recording showing a
single PICSI hyaluronan dot. Note accumulated sperm on
periphery, considered to be moribund. Tethered, motile sperm
for ICSI are selected from the more sparsely populated central
region. Reproduced from Biocoat original datasheets with
permission. HBS, HA-binding scores; PICSI, physiological
intracytoplasmic sperm injection.
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a PL; a live birth <37 weeks. Outcomes in experimental
and control arms will be compared using multivariable
logistic regression, adjusting for centre and for factors
used in the minimisation, with effects summarised as
ORs with 95% CIs. If there is evidence that the CPR
differs between the trial arms, then secondary analyses
will be carried out taking only women with a clinical
pregnancy as the denominator. In all cases, results of
primary analyses will be given more weight than those of
the secondary analyses.
Every attempt will be made to gather data on all
women randomised, irrespective of compliance with
the treatment protocol. If baseline assessments of cov-
ariates are missing, we will use mean values or missing
value indicators to replace them.37 If any outcome data
are missing, we will analyse only those with outcome
data, adjusting for baseline covariates. This approach is
unbiased if reasons for the outcome being missing can
be related to observed covariates (the so-called
‘missing at random’ assumption).36 If the primary
outcome is missing for >5% of couples, then a sensitiv-
ity analysis will be conducted to explore the ‘missing at
random’ assumption, using a pattern mixture
approach.38
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Exploratory analyses will investigate possible modiﬁers
of the treatment effect, including the factors used for
minimisation as well as sperm concentration (<15×106 vs
≥15×106) and hyaluronan binding score (>65% vs
≤65%). Depending on numbers available, we may also
compare very low (≤25%) and low (>25%, ≤65%) HBS
subgroups. In each case, an interaction test will ﬁrst be
used to determine whether there is a basis for investigat-
ing treatment efﬁcacy within subgroups. Subgroup ana-
lyses will be hypothesis generating only, and results will
be treated with caution.
As the two arms of this study are compatible with
the equivalent arms of the recent US NIH trial26 they
can be included in any future meta-analysis of the
data.
Mechanistic sample size and estimates
The mechanistic evaluation will be conducted through
a Structural Equation Modeling (SEM) approach that
is particularly well suited to estimating causal relation-
ships using a combination of quantitative data and
qualitative causal assumptions.39 40 DNA fragmentation
will be measured by the comet and acridine orange
assays and summarised through the latent variable
DNA fragmentation (ﬁgure 3A). Similarly, chromatin
compaction measured by aniline blue and CMA3 assays
will be summarised through the latent variable, chro-
matin compaction. HALO provides a separate covariate
of sperm nuclear integrity that contributes to both
latent variables. These two latent variables will then be
regarded as covariates in a regression model for HBS,
which in turn is a covariate for the logistic regressions
for each of the primary and secondary clinical out-
comes. This model is represented in ﬁgure 3B for
clarity. Other models where the two latent variables are
also covariates in the logistic regressions for the out-
comes will be considered where sufﬁcient samples are
available for robust estimation.
Evidence from blinded data suggests that 70% of
samples will permit two or more tests and therefore
some measure of both. On the basis of existing
reports,26 27 41 the beneﬁt of HA-ICSI may be greatest
for couples with the lowest HBS and the relationships
between HBS and the key outcomes will be non-linear.
Hence, interpretation of results of SEM could be com-
promised without considering a balanced HBS stratiﬁca-
tion of the samples. The proportion of samples in the
lowest stratum (estimated at 14% of all samples) is our
most constraining variable and has the strongest inﬂu-
ence on the ﬁnal sample size. Our current estimate for
the LBR within the lowest HBS stratum is 18%. Robust
estimates of the coefﬁcients within a logistic regression
have been thoroughly explored in simulation studies by
Peduzzi et al,42 where it was established that 10 events
per covariate are required. Consequently, within this
lowest HBS stratum we might expect 31 live births. The
Peduzzi rule42 requires at least 30 live births to robustly
estimate the coefﬁcients of three covariates; one for
HBS the variable of interest, one for treatment (ICSI/
PICSI) and one for the Nelson–Lawlor log odds of live
birth.43 These covariates are omitted from ﬁgure 3B for
clarity. Working back, we estimate that 1216 samples
balanced across all strata will be required to record at
least 30 live births in the lowest HBS stratum. This
ﬁgure is approximately half of all ﬁnally stored samples,
giving ample room for adjustment. Structural equation
modelling will be undertaken with the software MPLUS
V.7.4.
Figure 3 (A) Flow chart for mechanistic sample processing. (B) Structural equation modelling for mechanistic analyses. (A)
Residual sperm samples will be scored (HBS) before freezing and shipping to central storage (Birmingham BioBank; BBB). The
clinical trials unit (Pragmatic Clinical Trials Unit; PCTU) will select samples for analysis based on their HBS stratification (1) and
whether the sample is from a couple who achieved or did not achieve a clinical pregnancy (arm allocation blinded to the
investigating team). Those samples will then be assessed for further analyses following standard cytological evaluation (2). As
many tests of DNA fragmentation as possible will be carried out if sufficient sperm are available, by distributing (frozen) sample
aliquots between the three mechanistic study centres (Birmingham, Belfast and Leeds). Hierarchical priority of testing will be
Comet (3a)=TUNEL (3b)>HALO (4)=AO (5)>AB (6a)=CMA3 (6b). If sample is limiting, the revised testing priority requires at least
one assay of DNA fragmentation (3a preferred) and one assay of chromatin compaction (6b preferred) to be carried out. If there
is only sufficient sperm for one assay, then priority will be given to HALO (4) as its measure of DNA fragmentation is closely
dependent on chromatin compaction. These priorities may change as more data become available. (B) In brief, the Comet,
TUNEL and Acridine Orange assays measure sperm DNA fragmentation. The CMA3 and Aniline Blue assays measure sperm
chromatin compaction. HALO is a measure of DNA fragmentation and chromatin compaction. These latent variables will be
regarded as covariates in a regression model for HBS, which in turn is a covariate for the logistic regressions for each of the
primary and secondary clinical outcomes. The HBS will vary in relation to DNA fragmentation and chromatin compaction and will
then predict the key outcomes. Omitted from the diagram are other factors in this relationship that also influence outcomes,
namely the treatment given (ICSI/PICSI) and the couples concerned: Nelson and Lawler provide details of nine factors, some of
which are non-linear, but for which the chances of outcomes can be derived with an online routine (http://www.ivfpredict.com).
We propose to use the Nelson–Lawlor log odds as a single predictor variable rather than the nine factors. Note that we anticipate
the relationships between HBS, other factors, treatment and the key outcomes to be complex: potentially non-linear. To explore
this possibility, the samples will be stratified by HBS as follows: <50%, 50–65% and >65% (A). Note that for clarity, the path
diagram (B) focuses on only those variables specific to the mechanistic work. HBS, hyaluronan binding score; ICSI,
intracytoplasmic sperm injection; PICSI, physiological intracytoplasmic sperm injection.
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End point analyses
Primary end point analysis
The primary end point is the proportion of women
randomised who experience a live birth of ≥37 weeks.
This proportion has as its denominator the number
of women who are followed up after their ICSI cycle
following fresh embryo transfer (UK law permits up
to three) postrandomisation per arm. Its numerator is
the number of women who conceive and proceed to
have a live birth of ≥37 weeks. The proportion will be
compared between arms using multivariable logistic
regression adjusting for centre and for factors used in
the minimisation. An OR with 95% CI will be
calculated.
Secondary end point analyses
The secondary end points are the respective proportions
of women who:
▸ Experience a clinical pregnancy based on the pres-
ence of fetal heartbeat or fetal sac at 6–9 weeks’
gestation.
▸ Experience a clinical pregnancy and miscarry.
▸ Experience a clinical pregnancy and proceed to a live
birth of <37 weeks.
These proportions will follow the same calculations as
primary end point analysis.
Subgroup analyses
For binary outcomes, results will be expressed as OR
with 95% CIs of pregnancy success in either arm. The
exploratory subgroup analyses will follow minimisation
criteria as described in the ‘Randomisation’ section
above with addition of
▸ HBS (high (>65%) vs low (≤65%)),
▸ Sperm concentration (<15×106 vs ≥1×106).
We shall also analyse a very low (≤25%) versus low
(>25%, ≤65%) HBS subgroups. A more detailed clinical
statistical analysis plan (SAP) is provided in online
supplementary appendix 1. The more uncertain and
dynamic nature of the requirements for mechanistic
analyses excludes the provision of a detailed mechanistic
SAP before actual data acquisition begins. Readers are
referred to the ‘Mechanistic sample size and estimates’
section where some details of the statistical approach are
provided.
ETHICS AND DISSEMINATION
As HABSelect is a fertility study, both partners will need
to provide informed consent before being randomised
to the study. Clinical intervention is minimal and applies
to in vitro conducted process of sperm selection; simi-
larly, the mechanistic investigation will only make use of
the residual sperm left over after the treatment. Taking
these facts into consideration, the sponsor has deter-
mined that no additional ‘active’ monitoring for patient
safety and adverse event reporting is required and only
related unexpected serious adverse events (RUSAE) will
be reportable to ethics committees and sponsor. Every
attempt will be made to collect full follow-up data on all
couples, and it is anticipated that missing data will be
minimal due to routine nature of collected data and its
compliance with the pregnancy outcomes as required by
HFEA register.
HABSelect has obtained full approval from NHS
Research Ethics Committee (Ref 13/YH/0162) that
covers couples undergoing fully funded treatment as
well as the majority of private patients in the participat-
ing sites. It is being conducted in accordance with good
clinical practice principles, Declaration of Helsinki
(1996) and Research Governance Framework (2005).
It has also been endorsed by the major charity
Infertility Network UK, where support and advice via
patient participation will be sought on a regular basis.
The trial is registered with an authorised registry
(ISRCTN99214271) according to the ICMJE Guidelines
(http://www.icmje.org), and the authorship credit will
be on the substantial contributions as per the same
guidelines.
The Trial Steering Committee will agree a publication
plan and be consulted prior to release or otherwise
publish any study data. We anticipate that in addition to
the interim ﬁnal report required by the funder in Sept
2017 (open access), all outcomes from the study will be
submitted for peer review in the appropriate, open
access journals. Communications will also be delivered
at key international meetings associated with relevant
reproductive societies and groupings. Patients and other
stakeholders will also be able to obtain information on
their arm allocation after accessing a web site that will
be set up speciﬁcally for this purpose. As per Funder’s
requirements, all materials to be submitted for publica-
tion will be sent to the NIHR Coordinating Centre for
EME (NCCEMEM) for approval and prior to
publication.
Consent to the BioBank repository
Couples who are eligible to take part in the trial will also
be eligible to have their residual sperm samples stored
for future research in the University of Birmingham’s
established tissue bank called the Human Biomaterials
Resource Centre (HBRC), which collects and stores
human tissue samples for medical research.
Participation will be discussed with patients at the same
time as discussing their participation in the main trial.
Patients who agree to have residual sperm samples
stored will be asked to sign an additional consent form.
DISCUSSION AND CONCLUSIONS
HABSelect will be the largest male infertility trial under-
taken to date in the UK. Like most other studies, it has
strengths and limitations (see above). However, its cap-
ability to address a signiﬁcant unmet health need and
also advance mechanistic understanding and impact of
DNA integrity/fragmentation on clinical success in ICSI
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cannot be understated. In addition to HA-binding, alter-
native strategies to identify and select sperm for ICSI
include biophysical and morphometric methods based
on passive and active microﬂuidic chambers, zeta poten-
tial, high resolution imaging (IMSI and IMSOMI) and
magnetic cell sorting (MACS). Recent systematic reviews
with meta-analyses, however, found little evidence of efﬁ-
cacy with the caveat that all studies were either inad-
equately powered or were of low quality.29 44 45 The
most recent review of the literature on the efﬁcacy with
HA-selection also reported a lack of efﬁcacy but with the
same caveat applied.28
It may be difﬁcult to exclude sperm with such geno-
toxic DNA fragmentation altogether from ICSI proce-
dures; it is surely within our means, however, to
sufﬁciently eliminate them from the pool of those pre-
pared for ICSI. The HABSelect trial seeks to provide
robust evidence to ﬁrmly accept or reject the recom-
mendation of a prior HA-binding step in the selection
of sperm for ICSI and to determine whether such
selection does indeed mitigate for higher genotoxic
potential in patient samples. The study complies fully
with and extends on the NICE call for fertility guid-
ance: (http://www.nice.org.uk/newsroom/pressreleases/
NICEOutlinesReviewOfFertilityGuideline.jsp) and the
ESHRE call for new markers of sperm quality (https://
www.eshre.eu/~/media/sitecore-ﬁles/…/2012-January.
pdf?la=en).
It is difﬁcult to assess what impact the PICSI interven-
tion might have on the overall cost of treatment.
However, depending on the study outcomes, cost-
effectiveness modelling alongside an individual patient
data (IPD) meta-analysis may be considered.
Trial status
The ﬁrst patient was enrolled into HABSelect in
December 2013, and recruitment is due to end in
August 2016. The study is being conducted in 15 centres
across the UK. The trial report should be available in
the Autumn of 2017.
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